1st Quarter - Report

HUMANA, INC. for HUMANA INC

Firm
Client
Income
—
Expenses
$2,080,000
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

4 issue areas, each in the filer's own words, with who lobbied on it and where.

Medicare/Medicaid MMM

Medicare Advantage (MA) Policy and Reimbursement Enactment of policies in Calendar Year (CY) 2024 Medicare Advantage (MA) Capitation Rates and Part C and Part D Payment Policies Medicare Part D Issues Medicaid Policy Issues Including Redeterminations and Dual Eligibles Pharmacy Benefit Managers (PBM) and Pharmacy Policy and Reimbursement Issues Home Health Policy and Reimbursement Issues Implementation of Inflation Reduction Act of 2022 Public Law No. 117-169 S. 3018/H.R. 3173, Improving Seniors Timely Access to Care Act (117th Congress) Prior Authorization Policy and Regulatory Issues CMS-4185-F2 Medicare Advantage Risk Adjustment Data Validation Final Rule Primary Care and Value-Based Care Policy and Reimbursement Clinical Policy Issues Including Workforce and Mental Health Contract Year 2025 Policy and Technical Changes to the Medicare Advantage Plan Program, Medicare Prescription Drug Benefit Program, Medicare Cost Plan Program, and Programs of All-Inclusive Care for the Elderly, and Health Information Technology Standards (CMS-4205-P) Calendar Year (CY) 2024 Home Health Prospective Payment System Final Rule (CMS-1780-F) Calendar Year (CY) 2024 Medicare Physician Fee Schedule Final Rule (CMS-1784-F) Hospital Outpatient Prospective Payment System (OPPS): Remedy for the 340B-Acquired Drug Payment Policy for Calendar Years 2018-2022 Final Rule (CMS 1793-F) Fiscal Year (FY) 2025 Hospice Payment Rate Update Proposed Rule (CMS-1810-P) Fiscal Year (FY) 2025 Skilled Nursing Facility Prospective Payment System Proposed Rule (CMS 1802-P) Draft Calendar Year (CY) 2025 Part D Redesign Program Instructions Calendar Year (CY) 2025 Advance Notice for the Medicare Advantage (MA) and Medicare Part D Prescription Drug Programs Medicare Prescription Payment Plan: Final Part One Guidance on Select Topics, Implementation of Section 1860D-2 of the Social Security Act for 2025, and Response to Relevant Comments Medicare Prescription Payment Plan: Draft Part Two Guidance on Select Topics, Implementation of Section 1860D-2 of the Social Security Act for 2025, and Solicitation of Comments CMS Interoperability and Prior Authorization final rule (CMS-0057-F)

LobbyistCovered position, as disclosed
TIFFANY HAVERLY New Rep. Adrian Smith, Dep. COS/Sr. Advr.; Comms. Dir./Sr. Advr. Rep. Kay Granger, Strat. Comms. Advr. Rep. Greg Walden, Comms. Dir. Rep. Phil Roe, Comms. Dir.; Leg/Press/Staff Asst.; Leg. Corr. Rep. David Davis, Staff Asst.
VERONICA JACKSON —
JEFFREY LUNGREN —
RACHEL MAGNUSON —

Contacted: SENATE; Office of Management & Budget (OMB); Health & Human Services, Dept of (HHS); White House Office; HOUSE OF REPRESENTATIVES; Centers For Medicare and Medicaid Services (CMS)

Bills named: H.R. 3173 (118th), S. 3018 (118th)

Defense DEF

TRICARE Policy Issues including Telehealth, Value-Based Care, and T-5 Transition NDAA Implementation Policy Issues Veterans Healthcare and Policy Issues Implementation of National Defense Authorization Act for Fiscal Year 2024 Public Law No: 118-31

LobbyistCovered position, as disclosed
TIFFANY HAVERLY New Rep. Adrian Smith, Dep. COS/Sr. Advr.; Comms. Dir./Sr. Advr. Rep. Kay Granger, Strat. Comms. Advr. Rep. Greg Walden, Comms. Dir. Rep. Phil Roe, Comms. Dir.; Leg/Press/Staff Asst.; Leg. Corr. Rep. David Davis, Staff Asst.
VERONICA JACKSON —
JEFFREY LUNGREN —
RACHEL MAGNUSON —

Contacted: HOUSE OF REPRESENTATIVES; Veterans Affairs, Dept of (VA); SENATE; Defense, Dept of (DOD)

Taxation/Internal Revenue Code TAX

Tax Reform Implementation Issues

LobbyistCovered position, as disclosed
TIFFANY HAVERLY New Rep. Adrian Smith, Dep. COS/Sr. Advr.; Comms. Dir./Sr. Advr. Rep. Kay Granger, Strat. Comms. Advr. Rep. Greg Walden, Comms. Dir. Rep. Phil Roe, Comms. Dir.; Leg/Press/Staff Asst.; Leg. Corr. Rep. David Davis, Staff Asst.
VERONICA JACKSON —
JEFFREY LUNGREN —
RACHEL MAGNUSON —

Contacted: Treasury, Dept of; HOUSE OF REPRESENTATIVES; White House Office; SENATE

Pharmacy PHA

Prescription drug pricing Pharmacy Benefit Managers (PBM) and Pharmacy Policy and Reimbursement Issues

LobbyistCovered position, as disclosed
TIFFANY HAVERLY New Rep. Adrian Smith, Dep. COS/Sr. Advr.; Comms. Dir./Sr. Advr. Rep. Kay Granger, Strat. Comms. Advr. Rep. Greg Walden, Comms. Dir. Rep. Phil Roe, Comms. Dir.; Leg/Press/Staff Asst.; Leg. Corr. Rep. David Davis, Staff Asst.
VERONICA JACKSON —
JEFFREY LUNGREN —
RACHEL MAGNUSON —

Contacted: HOUSE OF REPRESENTATIVES; Health & Human Services, Dept of (HHS); Food & Drug Administration (FDA); Office of Management & Budget (OMB); Centers For Medicare and Medicaid Services (CMS); SENATE; White House Office

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.